cognitive impairment
Conditions
Interventions
MCI group:No intervention
healthy control group:No intervention
AD group:No intervention
Sponsors
Hubei Provincial Hospital of Integrated Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1)MCI group 1.Meets the diagnostic criteria for MCI; 2.Aged between 45 and 75; 3.Patient has a history of memory impairment for =3 months; 4.Right-handed; 5.Clear consciousness and able to cooperate with treatment and assessment; 6.MMSE score =24; 7.Participants must have received education for 6 years or more; 8.Informed consent and voluntary signing of the "Informed Consent Form" are required. (2) healthy control group 1.MMSE score = 25 points; 2.Aged between 45 and 75; 3.Normal cognition without significant complaints of memory decline or cognitive impairment; 4.Informed consent is required and participants must voluntarily sign the "Informed Consent Form". (3)AD group 1.Meet the diagnostic criteria for Alzheimer's disease. 2.Aged between 45 and 75 years. 3.MMSE score is =21. 4.Informed consent is obtained, and the participant voluntarily signs the "Informed Consent Form".
Exclusion criteria
Exclusion criteria: (1) MCI group 1.Patients with a history of mental illness such as schizophrenia, schizoaffective disorder, severe depression, or other major neurodegenerative dementias; 2.Patients with severe liver, kidney, hematological disorders or endocrine system primary diseases; 3.Patients with severe aphasia, significant visual impairment, visual field defects, spatial neglect, and hearing impairment who are unable to cooperate with treatment and related assessments; 4.Patients with cognitive impairment due to drugs or poisoning and other reasons; 5.Patients with metal implants in the body (such as metal prostheses, stents, pacemakers, etc.); 6.Patients with diseases such as claustrophobia or Meniere's syndrome that are not suitable for scanning; 7.Patients who are participating in other research trials that may affect the results of this study. (2) healthy control group 1.Patients with severe liver, kidney, blood disorders, and primary endocrine system diseases are excluded from the study. 2.Patients who cannot comply with treatment and related assessments are excluded. 3.Patients who are currently participating in other studies that may affect the results of this study are excluded. 4.Patients with metal implants in their bodies, such as metal prostheses, stents, pacemakers, etc., are excluded. 5.Patients with diseases that are not suitable for scanning, such as claustrophobia and Meniere's syndrome, are excluded. (3) AD group 1.Patients with severe liver, kidney, blood disorders, and primary endocrine system diseases are excluded from the study. 2.Patients who cannot comply with treatment and related assessments are excluded. 3.Patients who are currently participating in other studies that may affect the results of this study are excluded. 4.Patients with metal implants in their bodies, such as metal prostheses, stents, pacemakers, etc., are excluded. 5.Patients with diseases that are not suitable for scanning, such as claustrophobia and Meniere's syndrome, are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional near - infrared spectroscopy,fNIRS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment,MoCA;Mini-Mental State Examination,MMSE;Auditory Verbal Learning Test,AVLT;Pitsburgh sleep quality indexs,PSQI;fMRI;Serum amyloid beta protein-40;Serum amyloid beta protein-42;brain-derived neurotrophic factor,BDNF; | — |
Countries
China
Contacts
Public ContactXia Wenguang
Hubei Provincial Hospital of Integrated Chinese and Western Medicine
Outcome results
None listed